DOCSLIB.ORG

Calcitonin Gene-Related Peptide in the Human Hypothalamus The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Calcitonin Gene-Related Peptide in the Human Hypothalamus The Enaocrinol. Japon. 1989, 36(3),409-415 Calcitonin Gene-Related Peptide in the Human Hypothalamus KAZUHIRO TAKAHASHI, TORAICHI MOURI, MASAHIKO SONE, OSAMU MURAKAMI, KEIICHI ITOI, YUTAKA IMAI, MAKOTO OHNEDA, KAORU YOSHINAGA AND NOBUAKI SASANO* The Second Department of Internal Medicine and *the Department of Pathology, Tohoku University School of Medicine, Sendai, Miyagi, Japan Abstract Calcitonin gene-related peptide (CGRP)-like immunoreactivity (LI) in the human hypothalamus was investigated by radioimmunoassay and by im- munocytochemistry. CGRP-LI was detected from two hypothalami obtained at autopsy (2.1 and 7.0ng/g wet tissue) by radioimmunossay. Reverse phase high performance liquid chromatography revealed that most of the CGRP-LI in the human hypothalamus was eluted in an identical position with synthetic human CGRP. For immunocytochemistry, human hypothalami obtained at autopsy were fixed and cryostat-sectioned at 40ƒÊm. Free floating sections were immunostained with antibody to CGRP. CGRP-immunoreactive cell bodies were found in the supraoptic nucleus, paraventricular nucleus and in- fundibular nucleus. These findings indicate that CGRP exists in the cell bodies of the supraoptic nucleus, paraventricular nucleus and infundibular nucleus in the human hypothalamus and CGRP may play some roles in the endocrine and other functions of the human hypothalamus. Calcitonin gene-related peptide (CGRP) al., 1985; Skofitsch and Jacobowitz 1985; is a 37 amino acid peptide, which is encoded Mulderry et al., 1985; Okimura et al., 1987; by the same gene as calcitonin but is pro- Tiller-Borcich et al., 1988). In rat brain, duced by alternative splicing of the RNA high concentrations of CGRP-LI were re- transcript of the calcitonin gene (Amara et ported in the medulla oblongata (Mulderry al., 1982; Rosenfeld et al., 1983). et al., 1985), and immunoreactive CGRP By radioimmunoassay and immunocyto- was found in several nuclei of the brain chemistry, CGRP-like immunoreactivity (LI) stem and in their fibers projecting to the was shown to exist both in the central and hypothalamus (Rosenfeld et al., 1983). In peripheral nervous system (Rosenfeld et al., the rat hypothalamus, CGRP positive cell 1983; Wiesenfeld-Hallin et al., 1984; bodies were also observed in the paraventri- Tschopp et al., 1984 and 1985; Kawai et cular nucleus, arcuate nucleus, anterior nucleus, perifornical area and lateral area Received February 21, 1989 (Kawai et al., 1985; Skofitsch and Jacobo- Address all correspondence and reprint requests to, TORAICHI MOURI, M. D. The Second witz 1985). CGRP may act as a neuro- Department of Internal Medicine, 1-1 Seiryo-cho, transmitter or neuromodulator. Sendai, Miyagi, Japan 980 CGRP-LI was also determined in the Endocrinol.Japon. 410 TAKAHASHI et al. June 1989 human brain including the hypothalamus creatic polypeptide, peptide YY, substance P, secretin, glucagon, vasoactive intestinal poly- and the pituitary gland by radioimmunoas- peptide or angiotensin I (these peptides were say (Tschopp et al., 1985; Tiller-Borcich obtained from Peninsula laboratories, USA). The et al., 1988). However, no report is avai- sensitivity of this assay was 2.9•}0.5pg/tube lable on the localization of immunoreactive (n=4, mean•}SD). Intra- and interassay coe- CGRP cells in the human hypothalamus. fficientsof variation were 6.2% (n=10)and In the present study, we demonstrate the 11.3% (n=8), respectively. presence of CGRP-LI in the human hy- Fractionations of CGRP-LI in the human hy- pothalamus by radioimmunoassay and by pothalamus were carried out by reverse phase high immunocytochemistry. performance liquid chromatography (HPLC) on a Waters i Bondapak C18, 3.9X300mm column with a linear gradient from 30-60% solvent B Materials and Methods (solvent A=0.1% trifluoracetic acid/water; sol- vent B =0.1% trifluoracetic acid/acetonitrile) at a flow rate of 1ml/min. One ml fractions were Radioimmunoassay collected for radioimmunoassay. The hypothalami and the cerebral cortex (temporal lobe or occipital lobe) were obtained Immunocytoch ernistry at autopsy from 2 females aged 69 and 78 years Four human brain tissues were obtained at within 2 postmortem hours, and stored at -80•Ž autopsy from 2 males and 2 females aged 63-75 until extracted. Neither case had any endo- crinological or neurological disorder before death. years within 3 postmortem hours. They were immersed immediately in 10% formalin for 7-13 Each of the specimens was boiled in 1M acetic days. After macroscopical pathological examina- acid for 10 minutes, homogenized and centri- tions, the hypothalami were dissected out and fuged by 24000 Xg for 60 minutes. The super- refixed in a mixture containing 4% paraformal- natants were dried with air. Brain tissue ex- dehyde, 0.5% glutaraldehyde and 0.1% saturated tracts were reconstituted in assay buffer (0.1M picric acid in 0.01M phosphate-buffered saline phosphate buffer, pH7.4 containing 0.1% human serum albumin, 0.2% Triton X-100 and 0.1% (PBS) (pH 7.4) for 48 hours at 4•Ž. These 4 cases had no endocrinological or neurological sodium azide) and subjected to radioimmunossay. disorders. The hypothalamic tissues were rinsed The radioimmunoassay procedures for CGRP and immersed in 20% sucrose in 0.01M PBS were previously reported (Mouri et al., 1989). containing 0.05% dimethylsulfoxide and cut into The antibody to human CGRP was raised in a 40ƒÊm coronal frozen sections with a cryostat. rabbit. Synthetic human CGRP (Peninsula Sections were stored in 0.01M PBS containing Laboratories, USA) was conjugated with bovine 0.3% Triton X-100. thyroglobulin (Sigma Chemicals Co., USA) by carbodiimide. Conjugated CGRP was injected Free floating sections were immunostained into a rabbit with complete Freund's adjuvant. with antibody to human CGRP by the Vector The final dilution of the antibody was 1:80000. ABC system. Triton X-100 diluted in 0.01 M Synthetic human CGRP was used as the standard PBS to 0.3% was used for dilution and washing and synthetic human [Tyr0]-CGRP (Peninsula in the following procedures. The sections were Laboratories, USA) was used for iodination. incubated in 1% hydrogen peroxide for 60 1251-[Tyro]-CGRP was prepared by the modifica. minutes at room temperature, washed and then tion of the chloramine-T method (Hunter and incubated in 1% normal gout serum for 60 Greenwood, 1962) without the addition of sodium minutes at room temperature. The sections were metabisulfite. The radioimmunoassay showed incubated with the antibody to human CGRP 100% cross reaction with CGRP II (Steenbergh (1:10000) for 7 days at 4•Ž, then washed and et al., 1985) (Peninsula Laboratories, USA) and incubated in biotinylated secondary antibody to less than 0.001% with calcitonin, parathyroid rabbit IgG (1:400) (Vector, USA) for 16-20 hormone (1-84), human corticotropin-releasing hours at 4•Ž. The sections were again washed hormone, human growth hormone releasing and incubated in avidin-biotinated horseradish hormone, somatostatin, arginine vasopressin, peroxidase (Vector, USA) for 4 hours at room oxytocin, human neuropeptide Y, human pan- temperature, then washed and made to react 411 HYPOTHALAMUS Vol.36, No.3 CGRP IN HUMAN with 3,3'-diaminobenzidine tetrahydrochloride (DAB). The DAB reaction product was inten- si.(ed by cobalt chloride and nickel ammonium following the procedure described by Adams, J. C. (1981). The sections were mounted on glass slides coated with gelatin. Table 1. CGRP-LI content in the human hypothalamus and cerebral cortex of two cases. Fig.1. Reverse phase high performance liquid chromatography of CGRP-LI in a human hypothalamic extract. CGRP: the elution n.d.: Not detectable (<0.07ng/g wet tissue) *: Occipital lobe,**: Temporal lobe position of synthetic human CGRP. CGRP II: that of CGRP II. Results By radioimmunoassay, CGRP-LI was detected in 2 human hypothalami (2.1 and 7.0ng/g wet tissue), the amounts being greater than those in the cerebral cortex (Table 1). Serial twofold dilution curves of tissue ex- tracts were parallel' with a standard curve of CGRP. Reverse phase HPLC revealed that most of the CGRP-LI in the human hypothalamus was eluted in an identical position with synthetic human CGRP, which was later than that of CGRP II, while a small amount of CGRP-LI was eluted in a more hydrophilic position than the elution positions of CGRP and CGRP II (Fig. 1). By immunocytochemistry, Fig.2. CGRP immunoreactive cell bodies in the supra- moderate numbers of CGRP optic nucleus (X20). OT: optic tract, DL: pars immunoreactive cell bodies dorsolateralis, DM: pars dorsomedialis, VM: pars were found in the supraoptic ventromedialis. Endocrinol. Japon. 412 TAKAHASHI et al. June 1989 Fig.3. CGRP immunoreactive cell bodies in the pars dorsolateralis of the supraoptic nucleus (•~40). Fig.4. CGRP immunoreactive cell bodies in the pars dorsomedialis of the supraoptic nucleus (•~200). 413 Vol.36, No.3 CGRP IN HUMAN HYPOTHALAMUS ⇔ Fig.5. CGRP immunoreactive cell bodies in the paraven- tricular nucleus (X40). V: third ventricle nucleus (Fig.2-4). CGRP immunoreactive cell bodies were also found in the para- ventricular and infundibular nuclei, but the numbers of positive cells in these two nuclei were less than those in the supraoptic nucleus (Fig. 5,6). The absorption of CGRP antibody with a large amount of synthetic human CGRP (2.5,ƒÊg/l ml of 1:10000 CGRP antibody) for 3 hours at room temperature abolished im- munostaining completely. The pretreatment of CGRP anti- body with large amounts of corticotropin-releasing hor- mone, arginine vasopressin and oxytocin (2.5ƒÊg/l ml of 1:10000 CGRP antibody) did not in- fluence the immunostaining of CGRP. Normal rabbit serum (1:10000) instead of CGRP antibody did not show any positive immunostainings. ← Fig.6. CGRP immunoreactive cell bodies in the infundibularnucleus (•~100). Endocrinol. Japon. 414 TAKAHASHI et ol. June 1989 (Brain et al., 1985; Hanko et al., 1985). Discussion The infusion of CGRP reduced gastric acid output, pepsin secretion and plasma levels In this study, we detected CGRP-LI in of gastrin, gastric inhibitory peptide, entero- the human hypothalamus in a radioim- glucagon and neurotensin in man (Kraenzlin munoassay.
Load more

Recommended publications
  • Calcitonin Gene Products and the Kidney
    Kiinische Klin Wochenschr (1989) 67:870-875 W°chenchrif t © Springer-Verlag 1989 Calcitonin Gene Products and the Kidney A. Kurtz 1, R. Muff z, and J.A. Fischer z 1 Physiologic Institute, University of Ziirich, Switzerland 2 Research Laboratory for Calcium Metabolism, Departments of Orthopedic Surgery and Medicine, University of Ziirich, Ziirich, Switzerland Summary. Calcitonin gene-related peptide (CGRP) Calcitonin and CGRP are single chain polypep- is localized in capsaicin-sensitive nerve fibres in the tides consisting of 32 and 37 amino acids, respec- kidney and urogenital tract whereas calcitonin tively. They have in common amino-terminal ring reaches the kidney through the general circulation. structures linked by disulfide bridges and the car- Systemic infusion of CGRP and perfusion of iso- boxyltermini are amidated. In man, CGRP shares lated rat kidney reduces vascular resistance, and 16% structural homology with calcitonin whereas increases renal blood flow and glomerular filtra- the homology between CGRP-I and -II is 92% tion. CGRP stimulates renin secretion in vivo and [13]. As a result, distinct receptors for calcitonin in vitro and inhibits contraction of isolated rat me- and CGRP have been identified [7, 11, 33, 42]. sangial cells by angiotensin II. Calcitonin does not Human CGRP-I and -II, due to their high homolo- affect vascular resistance, renal blood flow and glo- gy, crossreact almost completely, but subtle differ- merular filtration, and is tess potent in stimulating ences in the distribution of human CGRP-I and renin secretion, and does not alter contraction of -II binding sites have been observed on receptor isolated rat mesangial cells by angiotensin II.
    [Show full text]
  • Oxytocin Is an Anabolic Bone Hormone
    Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10).
    [Show full text]
  • Neurotensin Activates Gabaergic Interneurons in the Prefrontal Cortex
    The Journal of Neuroscience, February 16, 2005 • 25(7):1629–1636 • 1629 Behavioral/Systems/Cognitive Neurotensin Activates GABAergic Interneurons in the Prefrontal Cortex Kimberly A. Petrie,1 Dennis Schmidt,1 Michael Bubser,1 Jim Fadel,1 Robert E. Carraway,2 and Ariel Y. Deutch1 1Departments of Pharmacology and Psychiatry, Vanderbilt University Medical Center, Nashville, Tennessee 37212, and 2Department of Physiology, University of Massachusetts Medical Center, Worcester, Massachusetts 01655 Converging data suggest a dysfunction of prefrontal cortical GABAergic interneurons in schizophrenia. Morphological and physiological studies indicate that cortical GABA cells are modulated by a variety of afferents. The peptide transmitter neurotensin may be one such modulator of interneurons. In the rat prefrontal cortex (PFC), neurotensin is exclusively localized to dopamine axons and has been suggested to be decreased in schizophrenia. However, the effects of neurotensin on cortical interneurons are poorly understood. We used in vivo microdialysis in freely moving rats to assess whether neurotensin regulates PFC GABAergic interneurons. Intra-PFC administra- tion of neurotensin concentration-dependently increased extracellular GABA levels; this effect was impulse dependent, being blocked by treatment with tetrodotoxin. The ability of neurotensin to increase GABA levels in the PFC was also blocked by pretreatment with 2-[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazole-3-yl)carbonylamino]tricyclo(3.3.1.1.3.7)decan-2-carboxylic acid (SR48692), a high-affinity neurotensin receptor 1 (NTR1) antagonist. This finding is consistent with our observation that NTR1 was localized to GABAergic interneurons in the PFC, particularly parvalbumin-containing interneurons. Because neurotensin is exclusively localized to dopamine axons in the PFC, we also determined whether neurotensin plays a role in the ability of dopamine agonists to increase extracellular GABA levels.
    [Show full text]
  • Purification of a Galanin Receptor from Pig Brain
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 3845-3849, May 1993 Neurobiology Purification of a galanin receptor from pig brain YAOHUI CHEN*, ALAIN FOURNIERt, ALAIN COUVINEAU*, MARC LABURTHE*, AND BRIGITTE AMIRANOFF*t *Laboratoire de Biologie and Physiologie des Cellules Digestives, Institut National de la Sant6 et de la Recherche Mddicale, U 239, 16 Rue Henri Huchard-75018 Paris, France; and tUniversitd du Quebec, Institut National de la Recherche Scientifique, INRS-Santd, 245 Boulevard Hymus, Pointe Claire, Qudbec, H9R1G6, Canada Communicated by Tomas Hokfelt, January 4, 1993 ABSTRACT A galanin receptor protein was solubilized lished data), we report the purification of a galanin receptor with 3-[(3-cholamidopropyl)dimethylammonio]-1-propane- from pig brain, a rich source of receptors that is available in sulfonate (CHAPS) from pig brain membranes and then pu- large amounts. This represents a basic step toward knowl- rified by single-step affinity chromatography. The product edge of the pharmacology and biochemistry of galanin re- exhibits saturable and specific binding for galanin with a ceptors and should lead to a better understanding of their binding activity of 17 nmol/mg of protein and a dissociation expression in the organism. constant (Kd) of 10 nM. This represents a 300,000-fold puri- fication over the detergent-solubilized fraction with a final recovery of 31% of the initial membrane galanin binding METHODS activity. Gel electrophoresis of the affinity-purified material Materials. Synthetic porcine galanin, glucagon, vasoactive showed a single polypeptide of 54 kDa by silver staining and intestinal peptide, synthetic neurotensin, substance P, baci- after radioiodination. Cross-linking of a purified fraction af- tracin, leupeptin, pepstatin A, GTP, GDP, guanosine 5'-[13,v- rmity-labeled with 125I-labeled galanin revealed a single band imido]triphosphate, cholesteryl hemisuccinate, 3-[(3-cholami- for the galanin-receptor complex at 57 kDa.
    [Show full text]
  • Neuroendocrinology 165P PC125 EFFECT of CALCITONIN GENE
    Poster Communication - Neuroendocrinology 165P PC125 PC127 EFFECT OF CALCITONIN GENE-RELATED PEPTIDE ON Effects of the potent hop-derived phytoestrogen, GnRH mRNA EXPRESSION IN THE GT1-7 CELL 8-prenylnaringenin, on the reproductive neuroendocrine axis 1 1 1 2 1 J. Kinsey-Jones ,X.Li ,J.Bowe ,S.Brain and K. O’Byrne J. Bowe1,J.Kinsey-Jones1,X.Li1,S.Brain2 and K. O’Byrne1 1Division of Reproductive Health, Endocrinology and Development, 1Division of Reproductive Health, Endocrinology and Development, Kings College London, London, UK and 2Centre for Cardiovascular King’s College London, London, UK and 2Centre for Cardiovascular Biology, Kings College London, London, UK Biology, King’s College London, London, UK Calcitonin gene-related peptide (CGRP) has recently been The phytoestrogen, 8-prenylnaringenin (8-PN), is the most potent shown to induce a profound suppression of the hypothala- phytoestrogen discovered to date. Derived from hops, it is pres- mic gonadotrophin-releasing hormone (GnRH) pulse gen- ent in dietary supplements currently marketed for natural breast erator, resulting in an inhibition of pulsatile luteinising hor- enhancement, though little is known about efficacy rates or other mone (LH) secretion in the rat (Li et al., 2004). The aims of effects (Coldham & Sauer, 2001). 8-PN is also of potential inter- the present study were, (i) to determine the presence of the est in the treatment of menopausal symptoms and diseases involv- CGRP receptor subunits, receptor activity modifying protein- ing angiogenesis. It is known that various phytoestrogens pro- 1(RAMP-1) and calcitonin receptor like receptor (CL), both duce inhibitory effects on gonadotrophin secretion in both of which are required for functional activity, in the GT1-7 humans and animals (McGarvey et al, 2001).
    [Show full text]
  • Injection Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use MIACALCIN injection safely and effectively. See full prescribing Injection: 200 International Units per mL sterile solution in 2 mL multi- information for MIACALCIN injection. dose vials (3) MIACALCIN® (calcitonin-salmon) injection, synthetic, for subcutaneous ----------------------------CONTRAINDICATIONS------------------------------ or intramuscular use Hypersensitivity to calcitonin-salmon or any of the excipients (4) Initial U.S. Approval: 1975 -----------------------WARNINGS AND PRECAUTIONS------------------------ -------------------------------RECENT MAJOR CHANGES----------------------- Serious hypersensitivity reactions, including reports of fatal anaphylaxis Indications and Usage (1.4) 03/2014 have been reported. Consider skin testing prior to treatment in patients with Warnings and Precautions (5.3) 03/2014 suspected hypersensitivity to calcitonin-salmon (5.1) ----------------------------INDICATIONS AND USAGE--------------------------- Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D (5.2) Miacalcin synthetic injection is a calcitonin, indicated for the following Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk conditions: of overall malignancies in calcitonin-salmon-treated patients (5.3, 6.1) Treatment of symptomatic Paget’s disease of bone when alternative Circulating antibodies to calcitonin-salmon
    [Show full text]
  • And Neurotensin-Immunoreactive Cells in the Gastrointestinal Tract of the Chicken
    Histol Histopath (1989) 4: 55-62 Histology and Histopathology The distribution and ontogeny of gastrin/CCK-, somatostatin- and neurotensin-immunoreactive cells in the gastrointestinal tract of the chicken B.C. Alison Department of Anatomy, Medical School, University of the Witwatersrand,Johannesburg, South Africa Summary. The distribution and time of appearance of wide variety of invertebrates and of vertebrates, cells with gastrin1CCK-, neurotensin- and somatostatin- especially mammals, (Rufener et al., 1975; Sundler et like immunoreactivity were studied in samples from al., 1977; Alumets et al., 1977; Helmstaedter et al., 1977; eight regions of the gastrointestinal tract of chick Seino et al., 1979). Studies on avian gut have been embryos from 11 days of incubation to hatching. No conducted at hatching (Rawdon and Andrew, 1981) and immunoreactive cells were found in any region at 11 thereafter in young birds, (Larsson et al., 1974) and days of incubation. Somatostatin- and neurotensin- adults (Aitken, 1958; Yamada et al., 1979). immunoreactive cells appeared for the first time in the Immunocytochemical studies have also demonstrated proventriculus, pyloric region and duodenum at 12 days immunoreactive cells of various types in early rat and of incubation with cells immunoreactive for neurotensin human foetal gut (Larsson et al., 1975; Dubois et al., occurring in the rectum at the same stage. GastrinICCK- 1976; Dubois et al., 1976; Larsson et al., 1977; Dupouy et immunoreactive cells were detected in the small intestine al., 1983; Kataoka et al., 1985). There is, however, much first at 14 days and in the pyloric region two days later. less published work on embryonic avian material; that of Cells immunoreactive for somatostatin and neurotensin Sundler et al.
    [Show full text]
  • Oxytocin Effects in Mothers and Infants During Breastfeeding
    © 2013 SNL All rights reserved REVIEW Oxytocin effects in mothers and infants during breastfeeding Oxytocin integrates the function of several body systems and exerts many effects in mothers and infants during breastfeeding. This article explains the pathways of oxytocin release and reviews how oxytocin can affect behaviour due to its parallel release into the blood circulation and the brain. Oxytocin levels are higher in the infant than in the mother and these levels are affected by mode of birth. The importance of skin-to-skin contact and its association with breastfeeding and mother-infant bonding is discussed. Kerstin Uvnäs Moberg Oxytocin – a system activator increased function of inhibitory alpha-2 3 MD, PhD xytocin, a small peptide of just nine adrenoceptors . Professor of Physiology amino acids, is normally associated The regulation of the release of oxytocin Swedish University of Agriculture O with labour and the milk ejection reflex. is complex and can be affected by different [email protected] However, oxytocin is not only a hormone types of sensory inputs, by hormones such Danielle K. Prime but also a neurotransmitter and a as oestrogen and even by the oxytocin 1,2 molecule itself. This article will focus on PhD paracrine substance in the brain . During Breastfeeding Research Associate breastfeeding it is released into the brain of four major sensory input nervous Medela AG, Baar, Switzerland both mother and infant where it induces a pathways (FIGURES 2 and 3) activated by: great variety of functional responses. 1. Sucking of the mother’s nipple, in which Through three different release pathways the sensory nerves originate in the (FIGURE 1), oxytocin functions rather like a breast.
    [Show full text]
  • Neurotransmitter and Neuropeptide Regulation of Mast Cell Function
    Xu et al. Journal of Neuroinflammation (2020) 17:356 https://doi.org/10.1186/s12974-020-02029-3 REVIEW Open Access Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review Huaping Xu1, Xiaoyun Shi2, Xin Li3, Jiexin Zou4, Chunyan Zhou5, Wenfeng Liu5, Huming Shao5, Hongbing Chen5 and Linbo Shi4* Abstract The existence of the neural control of mast cell functions has long been proposed. Mast cells (MCs) are localized in association with the peripheral nervous system (PNS) and the brain, where they are closely aligned, anatomically and functionally, with neurons and neuronal processes throughout the body. They express receptors for and are regulated by various neurotransmitters, neuropeptides, and other neuromodulators. Consequently, modulation provided by these neurotransmitters and neuromodulators allows neural control of MC functions and involvement in the pathogenesis of mast cell–related disease states. Recently, the roles of individual neurotransmitters and neuropeptides in regulating mast cell actions have been investigated extensively. This review offers a systematic review of recent advances in our understanding of the contributions of neurotransmitters and neuropeptides to mast cell activation and the pathological implications of this regulation on mast cell–related disease states, though the full extent to which such control influences health and disease is still unclear, and a complete understanding of the mechanisms underlying the control is lacking. Future validation of animal and in vitro models also is needed, which incorporates the integration of microenvironment-specific influences and the complex, multifaceted cross-talk between mast cells and various neural signals. Moreover, new biological agents directed against neurotransmitter receptors on mast cells that can be used for therapeutic intervention need to be more specific, which will reduce their ability to support inflammatory responses and enhance their potential roles in protecting against mast cell–related pathogenesis.
    [Show full text]
  • (Calcitonin-Salmon) Nasal Spray, for Intranasal Use Vitamin D (5.2) Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------- WARNINGS AND PRECAUTIONS ----------------------­ These highlights do not include all the information needed to use • Serious hypersensitivity reactions including anaphylactic shock have been MIACALCIN nasal spray safely and effectively. See full prescribing reported. Consider skin testing prior to treatment in patients with information for MIACALCIN nasal spray. suspected hypersensitivity to calcitonin-salmon (5.1) • Hypocalcemia has been reported. Ensure adequate intake of calcium and MIACALCIN® (calcitonin-salmon) nasal spray, for intranasal use vitamin D (5.2) Initial U.S. Approval: 1975 • Nasal adverse reactions, including severe ulceration can occur. Periodic nasal examinations are recommended (5.3) • Malignancy: A meta-analysis of 21 clinical trials suggests an increased ------------------------------ INDICATIONS AND USAGE --------------------------- risk of overall malignancies in calcitonin-salmon-treated patients (5.4, Miacalcin nasal spray is a calcitonin, indicated for the treatment of 6.1) postmenopausal osteoporosis in women greater than 5 years postmenopause • Circulating antibodies to calcitonin-salmon may develop, and may cause when alternative treatments are not suitable. Fracture reduction efficacy has not loss of response to treatment (5.5) been demonstrated (1.1) ------------------------------- ADVERSE REACTIONS -------------------------------­ Limitations of Use: Most common adverse reactions (3% or greater) are rhinitis, epistaxis and other • Due to the possible association between malignancy and calcitonin­ nasal symptoms, back pain, arthralgia, and headache (6) salmon use, the need for continued therapy should be re-evaluated on a periodic basis (1.2, 5.4) To report SUSPECTED ADVERSE REACTIONS, contact Mylan • Miacalcin nasal spray has not been shown to increase bone mineral Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1­ density in early postmenopausal women (1.2) 800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • Physiology of Hypothalamus and Pituitary
    Physiology of Hypothalamus and Pituitary Simge Aykan, PhD Department of Physiology Ankara University School of Medicine Pituitary Gland • Pituitary gland (hypophysis) is two different tissue types that merged during embryonic development • Anterior pituitary (adenohypophysis): true endocrine gland of epithelial origin • Posterior pituitary (neurohypophysis): extension of the neural tissue of the brain • secretes neurohormones made in the hypothalamus Pituitary Gland • Pituitary bridges and integrates the neural and endocrine mechanisms of homeostasis. • Highly vascular • Posterior pituitary receives arterial blood • anterior pituitary receives only portal venous inflow from the median eminence. • Portal system is particularly important in its function of carrying neuropeptides from the hypothalamus and pituitary stalk to the anterior pituitary. Posterior Pituitary • Storage and release site for two neurohormones (peptide hormones) • Oxytocin • Vasopressin (antidiuretic hormone; ADH) • Large diameter neurons producing hormones are clustered in hypothalamus at paraventricular (oxytocin) and supraoptic nuclei (ADH) • Secretory vesicles containing neurohormones transported to posterior pituitary through axons of the neurons • Stored at the axons until a release signal arrives • Depolarization of the axon terminal opens voltage gated Ca2+ channels and exocytosis is triggered • Hormones release to the circulation Posterior Pituitary • The posterior pituitary regulates water balance and uterine contraction • Vasopressin (ADH), is a neuropeptide
    [Show full text]
  • Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
    Journal of Nuclear Medicine, published on September 4, 2014 as doi:10.2967/jnumed.114.142000 CONTINUING EDUCATION Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors Clément Morgat1–3, Anil Kumar Mishra2–4, Raunak Varshney4, Michèle Allard1,2,5, Philippe Fernandez1–3, and Elif Hindié1–3 1CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France; 2University of Bordeaux, INCIA, UMR 5287, Talence, France; 3CNRS, INCIA, UMR 5287, Talence, France; 4Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and 5EPHE, Bordeaux, France Learning Objectives: On successful completion of this activity, participants should be able to list and discuss (1) the presence of bombesin receptors, neurotensin receptors, or neuropeptide-Y receptors in some major tumors; (2) the perspectives offered by radiolabeled peptides targeting these receptors for imaging and therapy; and (3) the choice between agonists and antagonists for tumor targeting and the relevance of various PET radionuclides for molecular imaging. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through October 2017.
    [Show full text]